Silenced AML gene reactivated in mice—no human trials yet

A silenced cancer-fighting gene in acute myeloid leukemia (AML) isn’t broken—it’s just turned off. Researchers at The Jackson Laboratory (JAX) demonstrated in mice that this epigenetic switch can be flipped back on, publishing their findings in Science Translational Medicine. The team targeted DLEU2, a gene often inactivated in AML, using CRISPR-based tools to reverse its silencing without altering the underlying DNA sequence.

This isn’t about fixing mutations but restoring function to intact genes. The approach sidesteps the collateral damage of chemotherapy, which kills healthy cells alongside malignant ones. Early signals suggest this could open a path to gentler AML therapies—if the mechanism translates to humans.

The study’s design carries critical limits. All experiments were conducted in mouse models and human cell lines, not patients. While the epigenetic editing tool worked in these controlled settings, AML’s complexity in live human systems—where gene silencing interacts with immune responses, stromal microenvironments, and clonal heterogeneity—remains untested.

For patients today, nothing changes. This is a preclinical study—a necessary step, but one that typically takes years to reach clinical trials. The FDA’s accelerated approval pathways for oncology drugs might shorten timelines, but only if Phase I trials confirm safety and dosing in humans.

What the study does offer is a research framework. By proving gene silencing can be reversed in AML, the JAX team provides a model to investigate similar mechanisms in other cancers or diseases like neurodegenerative disorders, where epigenetic dysfunction plays a role. The tool itself—a modified CRISPR system—could become a lab standard for probing silenced genes.

Yet the leap from mice to humans is fraught. Even if the technique works in early trials, delivering epigenetic editors to bone marrow—AML’s primary site—without off-target effects poses a major hurdle. The gene therapy field has seen promising preclinical results falter in clinical translation before.